Tag Archives: cardiac failure

ACC 2022

ACC 2022 | IVVE

ACC 2022 | IVVE

This randomized study aimed at assessing the flu vaccine vs placebo in patients with cardiac failure.  It included 5129 patients with cardiac failure randomized to receiving the flu vaccine annually for 3 years vs placebo.  Primary end point included cardiovascular death, non-fatal AMI, and stroke. There were no significant differences between both groups. However, pneumonia

ACC 2022

ACC 2022 | PROMPT-HF

Patients with cardiac failure with reduced ejection fraction (HFrEF) are sub treated when you look at guideline-directed medical therapy (GDMT).    The aim of this study was to assess if, using an electronic registry, we can alert treating physicians and optimize medical treatment.   100 healthcare professionals (doctors, nurses, etc) were randomized to receiving and alert

Educación Médica Women Interventions

08/03 | LATAM Network of Interventional Women: 4 Simultaneous Educational Activities!

SOLACI and the Latin American Interventional Women Group (Grupo MIL) continue to promote continuing medical education, in this case with four simultaneous activities organized with Medtronic and aimed at female interventional specialists. In this one-of-a-kind session, participants will have the opportunity to discuss clinical data and procedural techniques with experts. The event will be held on

ticagrelor vs. aspirina

Empagliflozin: Better Quality of Life for Patients with Cardiac Failure and Preserved Ejection Fraction

Empagliflozin has shown early and sustained improved quality of life (at least for a year) in patients with cardiac failure and preserved function. Patients with cardiac failure and preserved ejection fraction present a deteriorated quality of life. The EMPEROR-Preserved assessed the efficacy of Empagliflozin in several baseline health status assessments. HRQoL was measured using the

ACC 2021 | Sacubitril/valsartan no es superior al ramipril luego de un IAM

ACC 2021 | Sacubitril/Valsartan not Superior to Ramipril after AMI

The combination sacubitril/valsartan following high-risk AMI did not reduce the risk of cardiac failure or cardiovascular risk in patients compared against ramipril. These data were provided by the PARADISE-MI presented today during the scientific sessions at ACC 2021. The combination sacubitril/valsartan had gathered prior evidence (basically from the PARADIGM-HF) for its superiority in terms of total

V Heart Failure 2020

Discount for SOLACI Members – V Heart Failure Review 2020

On December 7 thru 12 SOLACI is holding the 5th International Round of Conferences 2020 on “Heart Failure and Pulmonary Hypertension: Management of hear failure in times of polypharmacy and artificial devices”.   The event will take place next week Monday thru Friday from 5 to 7 pm and Saturday 12 from 10 to 12 am

AHA 2020 | EMPATROPISM: Empagliflozina en no diabéticos con insuficiencia cardíaca

AHA 2020 | EMPATROPISM: Empagliflozin in Non-Diabetics with Cardiac Failure

Empagliflozin improves cardiac function, exercise capacity and quality of life in non-diabetic patients with cardiac failure and deteriorated ejection fraction.  These findings were presented during the scientific sessions at AHA 2020 and published simultaneously in JACC. EMPATROPISM outcomes are on the same line as other studies using sodium glucose 2 cotransporter inhibitors (SGLT2) which showed

AHA 2020 | AFFIRM-AHF: Suplemento de hierro y menos hospitalizaciones por insuficiencia cardíaca

AHA 2020 | AFFIRM-AHF: Ferric Carboxymaltose and Fewer Hospitalizations for Cardiac Failure

Correcting iron deficiency in patients with cardiac failure might reduce the risk of new hospitalizations according to the AFFIRM-AHF published in the Lancet and presented at AHA 2020. The combined primary end point of death and hospitalizations was not met; yet the study showed a significant reduction of 26% in hospitalization rate. Irrespective of the

ESC 2020 | La disfunción ventricular puede inclinar la balanza para decidir la revascularización

ESC 2020 | Revascularization Strategies: Ventricular Dysfunction Might Tilt the Scales

Patients included in the ISCHEMIA trial who had a history of cardiac failure or ventricular function deterioration will benefit from revascularization vs. optimal medical treatment. This is a pre-specified analysis of the paradigmatic ISCHEMIA trial. The ISCHEMIA was published in March 2020 in NEJM and went somewhat unnoticed due to the COVID-19 pandemic.  At the

Virtual ACC 2020 | COAPT: Better Quality of Life Translates into Harder End-Points

After transcatheter mitral valve repair with MitraClip, the COAPT patients saw improved quality of life, better survival rate and fewer hospitalizations for cardiac failure at long term follow-up.  Improved quality of life had already been presented, exactly one year ago at the ACC 2019. In that occasion, it was established that the MitraClip reduces symptoms

Top